Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12,\ 04/03/13,\ 04/03/1$ 

Tungs	sten Mining NL	
ABN		
67 152	2 084 403	
We (the	e entity) give ASX the following in	formation.
	1 - All issues t complete the relevant sections (attach shee	ets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be [ issued	Fully paid ordinary shares
2	Number of <sup>+</sup> securities issued or to be issued (if known) or maximum number which may be issued	4,500,000
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$0.04
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issued on the exercise of unlisted options in accordance with the terms of a prospectus that was announced to the market on 11 December 2016.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	29 November 2016
6с	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	53,985,427 equity securitie 40,990,284 equity securitie	
7	<sup>+</sup> Issue dates	10 October 2017	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	10 C S S S S S S S S S S S S S S S S S S	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	413,652,845	Fully paid ordinary shares. (Not incorporating the recently announced Entitlement Issue)

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	Lia
	+Class
51,489,394	Unlisted options exercisable at \$0.04, expiring on 31 December 2019
16,000,000	Unlisted Director Options:
	a) 3,200,000 unlisted options vested on grant, exercisable at \$0.04, expiring 23 December 2020,
	b) 3,200,000 unlisted options, vesting 23 December 2017, exercisable at \$0.05, expiring 20 December 2020,
	c) 9,600,000 unlisted options, vesting 23 December 2018, exercisable at \$0.06, expiring 20 December 2020.
9,250,000	Unlisted Employee Options:
	a) 1,850,000 unlisted options vested on grant, exercisable at \$0.04, expiring 6 February 2021.
	b) 1,850,000 unlisted options will vest on achievement of certain Key Performance Indicators and will have an exercise price of \$0.05, expiring 6 February 2021.
	c) 5,550,000 unlisted options will vest on achievement of certain Key Performance Indicators and will have an exercise price of \$0.06, expiring 6 February 2021.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

#### Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

13	Ratio in which the <sup>+</sup> securities will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of
17	Closing date for receipt of acceptances or renunciations

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements in full through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	their o	do security holders dispose of entitlements (except by sale that a broker)?	
33	<sup>+</sup> Issue	date	
		notation of securities supplete this section if you are applying	ng for quotation of securities
34	Type of tick of	of *securities one)	
(a)		*Securities described in Part 1	
(b)			f the escrowed period, partly paid securities that become fully paid, employeeds, securities issued on expiry or conversion of convertible securities
Entitie	s that	have ticked box 34(a)	
Additi	onal sec	curities forming a new class	of securities
Tick to		e you are providing the informati	on or
35			securities, the names of the 20 largest holders of the number and percentage of additional *securities held by
36		If the *securities are *equity *securities setting out the numb 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	securities, a distribution schedule of the additional per of holders in the categories
37		A copy of any trust deed for the	e additional *securities

<sup>+</sup> See chapter 19 for defined terms.

Entities	s that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another +security, clearly identify that other +security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	Number	<sup>+</sup> Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 10 October 2017

(Company Secretary)

In Eliel

Print name: Mark Pitts

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	263,652,708	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	131,826,354 ordinary shares pursuant to the non-renounceable entitlement issue	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	14,423,783 ordinary shares issued on exercise of unlisted options in accordance with the terms of the prospectus for a non-	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	renounceable entitlement issue that was announced to the market on 11 December 2016	
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid  +ordinary securities cancelled during that  12 month period	-	
"A"	409,902,845	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	61,485,427	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	3,750,000 issued as part consideration to Pilbara Minerals Limited for the acquisition of a modular processing plant announced	
• Under an exception in rule 7.2	to the ASX on 21 July 2017	
Under rule 7.1A	3,750,000 agreed to be issued as part	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	consideration to Pilbara Minerals Limited for the acquisition of a modular processing	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	plant announced to the ASX on 21 July 2017 (Note number of shares to be issued on 20 Mar 2018 may vary in accordance with the agreement)	
"C"	7,500,000	
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1		
"A" x 0.15	61,485,427	
Note: number must be same as shown in Step 2		
Subtract "C"	7,500,000	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	53,985,427	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
409,902,845		
0.10 Note: this value cannot be changed		
40,990,284		
of placement capacity under rule		

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	40,990,284
Subtract "E"  Note: number must be same as shown in Step 3	-
<b>Total</b> ["A" x 0.10] – "E"	40,990,284  Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.